» Articles » PMID: 26934577

Exome Sequencing of Oral Squamous Cell Carcinoma in Users of Arabian Snuff Reveals Novel Candidates for Driver Genes

Overview
Journal Int J Cancer
Specialty Oncology
Date 2016 Mar 3
PMID 26934577
Citations 25
Authors
Affiliations
Soon will be listed here.
Abstract

The study sought to identify genetic aberrations driving oral squamous cell carcinoma (OSCC) development among users of shammah, an Arabian preparation of smokeless tobacco. Twenty archival OSCC samples, 15 of which with a history of shammah exposure, were whole-exome sequenced at an average depth of 127×. Somatic mutations were identified using a novel, matched controls-independent filtration algorithm. CODEX and Exomedepth coupled with a novel, Database of Genomic Variant-based filter were employed to call somatic gene-copy number variations. Significantly mutated genes were identified with Oncodrive FM and the Youn and Simon's method. Candidate driver genes were nominated based on Gene Set Enrichment Analysis. The observed mutational spectrum was similar to that reported by the TCGA project. In addition to confirming known genes of OSCC (TP53, CDKNA2, CASP8, PIK3CA, HRAS, FAT1, TP63, CCND1 and FADD) the analysis identified several candidate novel driver events including mutations of NOTCH3, CSMD3, CRB1, CLTCL1, OSMR and TRPM2, amplification of the proto-oncogenes FOSL1, RELA, TRAF6, MDM2, FRS2 and BAG1, and deletion of the recently described tumor suppressor SMARCC1. Analysis also revealed significantly altered pathways not previously implicated in OSCC including Oncostatin-M signalling pathway, AP-1 and C-MYB transcription networks and endocytosis. There was a trend for higher number of mutations, amplifications and driver events in samples with history of shammah exposure particularly those that tested EBV positive, suggesting an interaction between tobacco exposure and EBV. The work provides further evidence for the genetic heterogeneity of oral cancer and suggests shammah-associated OSCC is characterized by extensive amplification of oncogenes.

Citing Articles

Massive parallel sequencing of head and neck conventional squamous cell carcinomas: A comprehensive review.

Nadal A, Cardesa A, Agaimy A, Almangush A, Franchi A, Hellquist H Virchows Arch. 2024; 485(6):965-976.

PMID: 39613893 PMC: 11666787. DOI: 10.1007/s00428-024-03987-2.


Mutant HRas Signaling and Rationale for Use of Farnesyltransferase Inhibitors in Head and Neck Squamous Cell Carcinoma.

Wang J, Al-Majid D, Brenner J, Smith J Target Oncol. 2023; 18(5):643-655.

PMID: 37665491 DOI: 10.1007/s11523-023-00993-3.


[Application value of whole exon sequencing and immune related indicators in the precision treatment of oral squamous cell carcinoma].

Xie S, Cai Z, Shan X Beijing Da Xue Xue Bao Yi Xue Ban. 2023; 55(4):697-701.

PMID: 37534654 PMC: 10398759.


Caspase activation in tumour-infiltrating lymphocytes is associated with lymph node metastasis in oral squamous cell carcinoma.

Bhosale P, Kennedy R, Watt F J Pathol. 2023; 261(1):43-54.

PMID: 37443405 PMC: 10772935. DOI: 10.1002/path.6145.


MFI2 upregulation promotes malignant progression through EGF/FAK signaling in oral cavity squamous cell carcinoma.

Yen W, Chang K, Chen C, Huang Y, Chen T, Cheng H Cancer Cell Int. 2023; 23(1):112.

PMID: 37309001 PMC: 10259005. DOI: 10.1186/s12935-023-02956-0.


References
1.
Freedman N, Abnet C, Caporaso N, Fraumeni Jr J, Murphy G, Hartge P . Impact of changing US cigarette smoking patterns on incident cancer: risks of 20 smoking-related cancers among the women and men of the NIH-AARP cohort. Int J Epidemiol. 2015; 45(3):846-56. PMC: 5005940. DOI: 10.1093/ije/dyv175. View

2.
Khan F, Pandian V, Ramraj S, Natarajan M, Aravindan S, Herman T . Acquired genetic alterations in tumor cells dictate the development of high-risk neuroblastoma and clinical outcomes. BMC Cancer. 2015; 15:514. PMC: 4496850. DOI: 10.1186/s12885-015-1463-y. View

3.
Youn A, Simon R . Identifying cancer driver genes in tumor genome sequencing studies. Bioinformatics. 2010; 27(2):175-81. PMC: 3018819. DOI: 10.1093/bioinformatics/btq630. View

4.
Gonzalez-Perez A, Lopez-Bigas N . Functional impact bias reveals cancer drivers. Nucleic Acids Res. 2012; 40(21):e169. PMC: 3505979. DOI: 10.1093/nar/gks743. View

5.
Orfanelli U, Jachetti E, Chiacchiera F, Grioni M, Brambilla P, Briganti A . Antisense transcription at the TRPM2 locus as a novel prognostic marker and therapeutic target in prostate cancer. Oncogene. 2014; 34(16):2094-102. DOI: 10.1038/onc.2014.144. View